Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

PURPOSE: MK-2206 is an oral, highly selective inhibitor of AKT. The safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of MK-2206 was evaluated in Japanese patients with advanced solid tumors. METHODS: Patients received a single oral dose of MK-2206 according to an every other day...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Chemother Pharmacol
Main Authors: Doi, Toshihiko, Tamura, Kenji, Tanabe, Yuko, Yonemori, Kan, Yoshino, Takayuki, Fuse, Nozomu, Kodaira, Makoto, Bando, Hideaki, Noguchi, Kazuo, Shimamoto, Takashi, Ohtsu, Atsushi
格式: Artigo
語言:Inglês
出版: Springer Berlin Heidelberg 2015
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4515243/
https://ncbi.nlm.nih.gov/pubmed/26104654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2810-z
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍